Cost-Effectiveness of Everolimus for Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal (GI) or Lung Origin -A Canadian Societal Health Care System Perspective
Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.2218
https://www.valueinhealthjournal.com/article/S1098-3015(16)33584-7/fulltext
Section Title :
Disease-Specific Studies
Section Order :
2105
First Page :
A734
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33584-7&doi=10.1016/j.jval.2016.09.2218